Transmitted resistance has become an important clinical problem in developed countries with long histories of antiretroviral use. In resource-limited settings, it is a foreseeable, if not insidiously emerging, issue. Any transmission route or currently approved antiretroviral drug may be involved. The clinical relevance of polymorphisms that commonly occur at sites known to be associated with resistance, and peculiarities of the non-B subtypes, are incompletely understood. Adverse clinical consequences that have been demonstrated with transmitted resistance include an increased risk of failing initial therapy and further development of resistance. Although treatment outcomes can be optimized by baseline resistance testing and virologic monitoring, these are impractical in most resource-limited settings at this time. The scale and impact of transmitted resistance can probably be reduced by comprehensive prevention and management strategies. Equally germane are epidemiological and clinical studies to extend understanding of the dynamics, clinical implications, and management of transmitted resistance.
Quinn TC, Wawer MJ, Sewankambo N., et al, for the Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med.2000;342:921-929.
2.
Tovanabutra S., Robison V., Wongtrakul J., et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr.2002;29:275-283.
3.
Blower SM, Ma L., Farmer P., Koenig S.Predicting the impact of antiretroviral in resource poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord.2003;3:345-353.
4.
Blower SM, Gershengorn HB, Grant RMA tale of two futures: HIV and antiretroviral therapy in San Francisco . Science. 2000;287:650-654.
5.
Velasco-Hernandez JX, Gershengorn HB, Blower SMCould widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis.2002;2:374-376.
6.
Fang Ct, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis.2004;190:879-885.
7.
Montaner Jsg , Hog R., Wood E., et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
8.
Elford J., Bolding G., Sherr L.High-risk sexual behavior increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS.2002;16:1537-1544.
9.
McGowan JP, Shah S., Ganea C., et al. Risk behavior for transmission of HIV among HIV-seropositive individuals in an urban setting. Clin Infect Dis.2004;38:122-127.
10.
Erbelding E. , Chung S., Kamb M., Irwin K., Rompalo A.New sexually transmitted diseases in HIV-infected patients: markers for ongoing HIV transmission behaviour. J Acquir Immune Defic Syndr.2003 ;33:247-252.
11.
Blower S., Bodine E., Kahn J., McFarland W.The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19(1):1-14.
12.
Zhang H., Dornadula G., Beumont M., et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med.1998;339:1803-1809.
13.
Lee EJ, Kantor R., Zijenah L., et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis.2005;192(7):1260-1264.
14.
Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F., Alcora M., Fiscus SAResistance of HIV-1 to antiretroviral agents in blood or seminal plasma: implications for transmission. AIDS. 1998;12(15):F181-F189.
15.
Brenner B., Routy JP, Quan Y., et al. Persistence of multidrug-resistant HIV-1 in transmitted infection leading to superinfection. AIDS. 2004;18(12):1653-1660.
16.
Choudhury B. , Pillay D., Taylor S., Cane PAAnalysis of HIV-1 variation in blood and semen during treatment and treatment interruption. J Med Virol.2002;68(4):467-472.
17.
Erice A., Mayers DL, Strike DG, et al. Brief report: transmitted infection with zidovudine-resistant human immunodeficiency virus type 1 [see Comments]. N Engl J Med.1993;328:1163-1165.
18.
Peuchant O., Capdepont S., Ragnaud JM, et al. Transmitted resistance to enfuvirtide in recently infected, antiretroviral-naïve patients, ANRS C03 Aquitaine Cohort. Antivir Ther.2006;11:S108.
19.
Yerly S., von Wyl V., Boni J., et al. Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology approach. Antivir Ther.2006;11:S118.
20.
Oette M., Kaiser R., Daumer M., et al. Trends of transmitted drug resistance in chronically HIV-infected patients in Germany, 2001-2005. Antivir Ther.2006;11:S125.
21.
Wensing Amj , Vercauteren J., van de Vijver DA, et al. Transmission of drug-resistance in Europe is characterized by single mutations and revertants . Antivir Ther.2006;11:S111.
22.
Little SJ, May S., Hecht F., et al. Increase in transmitted NNRTI drug resistance among recently HIV infected patients from North America and Australia. Antivir Ther.2006;11:S110.
23.
Truong HM, Klausner JD, Hecht FM, Grant TMReduced levels of transmitted resistance to NRTIs in San Francisco is discernable using two independent sentinel populations. Antivir Ther.2006;11:S115.
24.
Cane P., Christie I., Dunn D., et al. Time trends in transmitted resistance to HIV drugs in the United Kingdom: multicenter observational study. BMJ.2006;332(7534):179-180.
25.
Brindeiro R. , Vanderborght B., Caride E., et al. Sequence diversity of the reverse transcriptase of human immunodeficiency virus type 1 from untreated Brazilian individuals. Antimicrob Agents Chemother.1999;43:1674-1680.
26.
Brindeiro RM , Diaz RS, Sabino EC, et al. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS. 2003;17:1063-1069.
27.
Dumans AT, Soares MA, Pieniazek D., et al. Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naive HIV-1-positive individuals in Rio de Janeiro, Brazil. AntimicrbAgents Chemother.2002;46:3075-3079.
28.
Pires IL, Soares MA, Esperanza FA, et al. Prevalence of HIV-1 drug resistance mutations and subtypes in drug-naïve infected individuals in the Army Health Service of Rio de Janeiro , Brazil. J Clin Micobiol. 2004;42(1):426-430.
29.
Turner D., Wainberg M.HIV transmission and transmitted drug resistance. AIDS Rev.2006;8(1):17-23.
30.
de Mendoza C., Rodríguez C., Eiros J., et al. Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV . Clin Infect Dis.2005;41:227-232.
31.
Duwe S., Brunn M., Altmann D., et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy naive patients of the German seroconverter study. J Acquir Immune Defic Syndr. 2001;26:266-273.
32.
UK Collaborative Group of Monitoring the Transmission of HIV Drug Resistance.Analysis of prevalence of HIV-1 drug resistance in transmitted infections in the United Kingdom. BMJ.2001;322:1087-1088.
33.
Little SJ, May S., Hecht F., et al. Increase in transmitted NNRTI drug resistance among recently HIV-1 infected patients from North America and Australia. Antivir Ther.2006;11:S110 (abstract 97).
34.
Eshleman SH , Mracna M., Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS.2001;15:1951-1957.
35.
Eshleman SH , Hoover DR, Hudelson SE, et al. Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis.2006;193(4):479-481.
36.
Kamkamidze G., Sullivan T., Charbonneau T.Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants. J Clin Virol. 2001;12(1):143-148.
37.
Bauer GR, Colgrove RC, LaRussa PS, et al. Antiretroviral resistance in viral isolates from HIV-transmitting mothers and their infants. AIDS. 2006;20:1707-1712.
38.
de Mendoza C., Rodriguez C., Corral A., et al. Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes . Clin Infect Dis.2004; 39(8):1231-1238.
39.
Yerly S., Jost S., Telenti A., et al. Are drug-resistant variants transmitted with lower efficiency than wild-type? In: Program and Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; 2003. Abstract 145.
40.
Deeks SG, Wrin T., Liegler T., et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia . N Engl J Med.2001;344:472-480.
41.
Martinez-Picado J., Savara AV, Sutton L., D'Aquila RTReplicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol.1999;73:3744-3752.
42.
Dykes C., Fox K., Lloyd A., Chiulli M., Morse E., Demeter LMImpact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology. 2001;285:193-203.
43.
Gandhi RT, Wurcel A., Rosenberg ES, et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis.2003;37:1693-1698.
44.
Brenner BG, Routy JP, Petrella M., et al. Persistence and fitness of multi-drug resistant human immunodeficiency virus type 1 acquired in transmitted infection. J Virol.2002;76(4): 1753-1761.
45.
Yerly S., Jost S., Telenti A., et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther.2004;9(3):375-384.
46.
McCutchan FEGlobal epidemiology of HIV. J Med Virol.2006;78(Suppl 1):S7-S12.
47.
Becker-Pergola G., Kataaha P., Johnston-Dow L., et al. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retrovir.2000 ;16(8):807-813.
48.
Cornelissen M., van den Burg R., Zorgdrager F., Lukashov V., Goudsmit J.Pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol.1997;71:6348-6358.
49.
Soares MS, Brindero RM, Tanuri A.Primary HIV-1 drug resistance in Brazil. AIDS. 2004;18(Suppl 3):S9-S13.
50.
Wensing AM, van de Vijver DA, Angarano G., et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis.2005;192:958-966.
51.
Frater AJ, Beardall A., Ariyoshi K., et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients . AIDS. 2001;15(12):1493-1502.
52.
Ghosn J., Pellegrin I., Goujard C., et al. HIV-1 resistant strains acquired at the time of transmitted infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS. 2006;20(2):159-170.
53.
Coffin J.HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science.1995;267: 483-489.
54.
De Ronde A.,van Dooren M., van der Hoek L., et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol.2001;75:595-602.
55.
Garcia-Lerma JG, Nidtha S., Blumoff K., et al. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naïve persons. Proc Natl Acad Sci U S A. 2001;98:13907-13912.
56.
Pao D., Andrady U., Clarke J., et al. Long-term persistence of transmitted genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2004;37(5):1570-1573.
57.
Barbour JD, Hecht FM, Wrin T., et al. Persistence of transmitted drug resistance among recently HIV-1 infected adults. AIDS. 2004;18(12):1683-1689.
58.
Little SJ, Koelsch KK, Ignacio CC, et al. Persistence of transmitted drug-resistant virus among subjects with transmitted HIV infection deferring antiretroviral therapy. In: 11th Conf Retrovir Opportunistic Infect; February 8-11, 2004; 11 abstract no 36LB.
59.
Conlon CP, Klenerman P., Edwards A., et al. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance. J Infect Dis.1994;169:411-415.
60.
Smith DM, Wong JK, Mai HT, et al. Slow reversion of HIV transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in semen. Antivir Ther.2005;10(Suppl 1):S128.
61.
Flys T., Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012 . J Infect Dis.2005;192(1):24-29.
62.
Pillay D., Bhaskaran K., Jurriaans S., et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS . 2006;20(1):21-28.
63.
Little SJ, Holt S., Routy J., et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med.2002;347:385-394.
64.
Borroto-Esoda K., Harris J., Waters J., et al. Baseline genotype as a predictor of virological failure in patients receiving emtricitabine once daily or stavudine twice daily in combination with didanosine and efavirenz . In: 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco, CA. Abstract 672.
65.
Chaix ML, Desquilbet L., Cottalorda J., et al. Sub-optimal response to HAART in patients treated at time of transmitted HIV-1 infection and infected with HIV resistant strains. Antivir Ther.2005;10:S127. Abstract 114.
66.
Violin M., Cozzi-Lepri A., Velleca R., et al. Risk of failure in patients with 215 HIV-1 revertants starting their first thymi-dine analog-containing highly active antiretroviral therapy . AIDS. 2004;18:227-235.
67.
McColl D., Margot N., Lu B., et al. Lack of resistance to tenofovir at week 48 and impact of baseline resistance mutations on treatment response in study 934. 3. In: IAS Conference on HIV Pathogenesis and Treatment; 2005; Rio de Janeiro. Abstract TuPp0305.
68.
Grant RM, Hecht FM, Warmerdam M., et al. Time trends in transmitted HIV-1 drug resistance among recently infected persons. JAMA.2002;288(2):181-188.
69.
Mihailidis C., Dunn D., Pillay D., et al. Transmission of HIV-1 containing V118I in reverse transcriptase does not compromise response to first-line therapy . Antivir Ther.2004 ;9:S117. Abstract 106.
70.
Schmitz T., Kleinkauf N., Klempa B., Ringe H., Varnholt V., Grosch-Wörner I.Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child. Pediatr Infect Dis J.2006;25(3):275.
71.
Oette M., Kaiser R., Daumer M., et al. Transmitted HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr. 2006; 41:573-581.
72.
Shet A., Berry L., Mohri H., et al. Tracking the prevalence of transmitted antiretroviral Drug resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr . 2006;41:439-446.
73.
Johnson JA, Li JF, Wei X., et al. Baseline detection of low-frequency drug resistant mutations is strongly associated with virological failure in previously antiretroviral naive HIV-1 infected persons. Antivir Ther.2006;11:S79.
74.
Lange Jma, Perriens J., Kuritzkes D., et al. What policymakers should know about drug resistance and adherence in the context of scaling-up treatment of HIV infection. AIDS. 2004; 18(Suppl 3):S69-S74.
75.
Blower S., Bodine E., Kahn J., McFarland W.The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19(1):1-14.
76.
Petersen ML , Boily MC, Bastos FIAssessing HIV resistance in developing countries: Brazil as a case study. Rev Panam Salud Publica.2006;19(3):146-156.
77.
Lazzari S., de Felici A., Sobel H., Bertagnolio S.HIV drug resistance surveillance: summary of an April 2003 WHO consultation . AIDS.2004;18(Suppl 3):S49-S53.
78.
Sax PE, Islam R., Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients?: a cost-effectiveness analysis. Clin Infect Dis.2005;41(9):1316-1323.
79.
Bennet DE, Smith AJ, McCormick L., et al. Categorization of transmitted HIV drug resistance using the WHO/CDC HIV drug resistance threshold survey method. Antivir Ther.2006; 11:S116.
80.
Paterson DL , Swindells S., Mohr J., et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med.2000;133:21-30.
81.
Bangsberg DR , Acosta EP, Gupta R., et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006 ;20(2):223-231.
82.
Carrieri MP , Raffi F., Lewden C., et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther.2003 ;8:37-46.
83.
Bangsberg DR , Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations . AIDS.2003;17:1925-1932.
84.
Walsh JC, Pozniak AL, Nelson MR, Mandalia S., Gazzard BGVirologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J Acquir Immune Defic Syndr. 2002;30: 278-287.
85.
Mills EJ, Nachega JB, Buchan I., et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA.2006 ;296(6):679-690.
86.
Nemes Mib, Carvalho HB, Souza Mfm, and the QualiaidsGroup. Antiretroviral therapy adherence in Brazil. AIDS. 2004;18(Suppl 3):S15-S20.
87.
Koenig SP, Leandre F., Farmer PEScaling-up HIV treatment programmes in resource-limited settings: the rural Haiti experience. AIDS. 2004;18(Suppl 3):S21-S25.
88.
Coetzee D., Boulle A., Hildebrand K., Asselman V., Van Cutsem G, Goemaere E.Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS . 2004;18(Suppl 3):S27-S31.
89.
Nachega JB, Knowlton AR, Deluca A., et al. Treatment supporters to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study. J Acquir Immune Defic Syndr.2006;43(Suppl 1):S127-S133.
90.
Kazatchkine M.Antiretroviral treatment for HIV-infected patients in developing countries . In: Sixth International Congress on Drug Therapy in HIV Infection ; Glasgow, UK; November 17-21, 2002. Abstract KL 1.
91.
Adje-Toure CA , Calestin BA, Hanson DB, et al. Prevalence of genotypic and phenotypic HIV-1 resistant strains among patients who have rebound in viral load while receiving antiretroviral therapy in the UNAIDS-Drug Access Initiative in Abidjan, Côte d'Ivoire. AIDS. 2003;17(Suppl 3):S23-S29.
92.
Richman DD, Haulir D., Corbeil J., et al. Nevirapine resistance mutations of HIV type 1 selected during pregnancy. J Virol.1994;68:1660-1666.
93.
Delaugerre C., Rohban R., Simon A., et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol.2001;65(3):445-448.
94.
Bacheler L. , Jeffrey S., Hanna G. et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol.2001;75:4999-5008.
95.
U.S. Department of Health and Human Services.Guidelines for the Use of Antiretroviral. Agents in HIV-1-Infected Adults and Adolescents. May 4, 2006. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed September 27, 2006.
96.
BHIVA Guidelines for the Treatment of HIV-Infected Adults With Antiretroviral Therapy. Available at: http://www.bhiva.org/guidelines/2005/HIV/resistancetesting.html . Accessed September 27, 2006.
97.
Vandamme AM , Sonnerborg A., Ait-Khaled M., et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther.2004;9(6):829-848.
